Furthermore, CML patients responsive to TKI therapies, such as imatinib, nilotinib, and dasatinib, show a decrease in the number of M-MDSCs concomitant with a reduced immunosuppressive function in T-cell and NK cells, in conjunction with ABL-BCR1 transcript reduction [187]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.